Carelon is emerging as a key pillar of Elevance Health's long-term growth strategy, contributing around 36.3% of total operating revenues. The segment combines AI, predictive analytics, and coordinated care programs to reduce hospital readmissions by 20% and generate over 10% savings in post-acute care costs. Despite a 3.8% year-over-year decline in first-quarter 2026 operating gain due to lower affiliated health plan membership and investments in risk-based programs, specialty pharmacy and integrated solutions continue to gain traction. Elevance Health raised its 2026 adjusted EPS guidance to at least $26.75, supported by a 1.5% rise in first-quarter operating revenues. Competitors UnitedHealth and Humana are also scaling integrated care models, with UnitedHealth's revenues up 2% and Humana's up 23.5% in the same period.
Humana Inc
UnitedHealth Group IncorporatedElevance Health IncElevance Health raised its 2026 adjusted EPS guidance to at least $26.75, supported by revenue growth and Carelon's contributions.